What Is 5-Amino-1MQ?
5-Amino-1-methylquinolinium (5-Amino-1MQ) is a small-molecule inhibitor of Nicotinamide N-Methyltransferase (NNMT) — an enzyme that consumes SAM (S-adenosylmethionine) to methylate nicotinamide, producing 1-methylnicotinamide and reducing cellular NAD+ availability. By blocking NNMT, 5-Amino-1MQ raises intracellular NAD+ and SAM levels, activating longevity-associated metabolic pathways.
Mechanism of Action
NNMT is highly expressed in white adipose tissue and acts as a metabolic rheostat — high NNMT activity correlates with obesity, insulin resistance, and reduced cellular energy expenditure. By inhibiting NNMT, 5-Amino-1MQ shifts adipose tissue toward a more metabolically active state: increased mitochondrial biogenesis, enhanced fatty acid oxidation, and activation of SIRT1 and other NAD+-dependent enzymes including PARPs and CD38.
Fat Loss and Metabolic Research
In animal studies, 5-Amino-1MQ administration produced significant reductions in fat mass without changes in lean body mass or food intake. Treated animals showed increased energy expenditure, improved glucose tolerance, and reduced adipocyte size — effects occurring at doses that produced no observable toxicity.
Comparison with NMN/NR
While NMN and NR raise NAD+ by providing precursors, 5-Amino-1MQ raises NAD+ by reducing its consumption — a complementary mechanism that some researchers combine with NAD+ precursor supplementation for potentially additive effects on cellular NAD+ levels.
Quick Reference
Member reference tables summarize the compound's research parameters.
Research Indications
Research Protocols
As reported in cited literature and research-community logs (see Research Citations below), not a personal dosing recommendation.
This member section describes parameters reported in the research literature.
Peptide Interactions
This member section summarizes reported compound interactions and evidence limitations.
Reported Research Time Points
This member section summarizes reported research time points.
Safety Notes
Included for harm-reduction awareness only, in the event this compound is encountered outside its labeled research use. Inclusion here does not imply RUO Codes endorses, recommends, or instructs human use.
This member section discusses research safety considerations and uncertainties.
Quality Indicators
Research Citations
- Muscle Function in Aged Mice (2024)
Animal study | 10mg/kg/day SubQ | 8 weeks - Rat Pharmacokinetics Study (2021)
Animal PK study | Various doses | Bioavailability - Mouse Obesity Study - Neelakantan et al. (2018)
Animal study | 20mg/kg TID (60mg/kg/day) | 11 days | n=10 mice/group